Compare WTTR & OCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WTTR | OCS |
|---|---|---|
| Founded | 2016 | 2003 |
| Country | United States | Switzerland |
| Employees | N/A | 60 |
| Industry | Oilfield Services/Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.8B |
| IPO Year | 2017 | N/A |
| Metric | WTTR | OCS |
|---|---|---|
| Price | $18.61 | $30.09 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | $16.67 | ★ $42.00 |
| AVG Volume (30 Days) | ★ 1.8M | 458.9K |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.65% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | ★ $1,528,930,000.00 | N/A |
| Revenue This Year | $2.11 | $466.06 |
| Revenue Next Year | $4.94 | $479.73 |
| P/E Ratio | $69.16 | ★ N/A |
| Revenue Growth | ★ 120.79 | N/A |
| 52 Week Low | $7.82 | $16.00 |
| 52 Week High | $18.50 | $34.48 |
| Indicator | WTTR | OCS |
|---|---|---|
| Relative Strength Index (RSI) | 72.79 | 57.15 |
| Support Level | $16.26 | $25.95 |
| Resistance Level | N/A | $30.68 |
| Average True Range (ATR) | 0.68 | 1.49 |
| MACD | 0.13 | 0.29 |
| Stochastic Oscillator | 92.94 | 51.20 |
Select Water Solutions Inc provides sustainable water-management solutions to the energy industry in the United States. These solutions are supported by the company's critical water infrastructure assets, chemical manufacturing, and water treatment and recycling capabilities. The company's reportable segments are Water Services, Water Infrastructure, and Chemical Technologies. It generates maximum revenue from the Water Services segment, which comprises its short-cycle, field-based service offerings, including water transfer, water sourcing, fluids hauling, monitoring, containment, water-network automation, and the services associated with Peak Rentals. This segment earns revenue via market-based day rates, time-and-materials, or per-barrel delivered under MSAs and short-term work orders.
Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company has locations in five countries: Switzerland, Iceland, France, U.S. and Hong Kong.